Trial Profile

A phase I study assessing BLU-808 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BLU 808 (Primary)
Indications Chronic urticaria
Focus Adverse reactions

Most Recent Events

13 Feb 2025 According to a Blueprint Medicines media release, data from this study will be presented at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress.
12 Jan 2025 According to a Blueprint Medicines media release, detailed data will be presented at the J.P. Morgan conference on January 13, 2025.
12 Jan 2025 Results presented in a Blueprint Medicines Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com